Table.

Reported Cases of SGLT2 Inhibitor Use Associated With euDKA and Low-Carbohydrate Diets in Patients With T2DM

Patient age (y)	Gender	Number of years patient had T2DM	Number of days on a low-carbohydrate diet before developing euDKA	Number of days patient took SGLT2 inhibitor before developing euDKA	Plasma blood glucose (mg/dL) on admission to the hospital for euDKA	HbA1C at the time of admission for euDKA	Number of days patient required insulin drip	Reference
32	Female	22	∼3960	13	191	9.3% (78 mmol/mol IFCC)	Unknown	17
44	Male	16	Unknown	3-4	180	9.3% (78 mmol/mol)	Unknown	18
64	Female	Unknown	60	365	∼185.59	7.5% (58 mmol/mol IFCC)	Unknown	19
73	Male	10	7	Unknown	Unknown Point-of-care blood glucose: 143	Unknown	Unknown	20
31	Female	Unknown	14	Unknown	139	Unknown	Unknown	21
34a	Male	>5	7	∼60	251	HbA1C 8.2% (66 mmol/mol IFCC)	3
47a	Female	∼0.17	∼60	1	187	HbA1C 13.6% (125 mmol/mol IFCC)	5

Abbreviations: euDKA = euglycemic diabetic ketoacidosis; HbA1C = hemoglobin A1C; IFCC = International Federation of Clinical Chemistry and Laboratory Medicine; SGLT2 = sodium-glucose cotransporter-2; T2DM = type 2 diabetes mellitus.

^aPatient case 1 and 2 from our report included for comparison.